Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $217.16M |
| Gross Profit (TTM) | $194.16M |
| EBITDA | $-196.17M |
| Operating Margin | -87.10% |
| Return on Equity | -101.20% |
| Return on Assets | -29.80% |
| Revenue/Share (TTM) | $3.28 |
| Book Value | $1.80 |
| Price-to-Book | 57.06 |
| Price-to-Sales (TTM) | 33.52 |
| EV/Revenue | 31.27 |
| EV/EBITDA | -12.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 83.80% |
| Shares Outstanding | $68.59M |
| Float | $55.67M |
| % Insiders | 0.77% |
| % Institutions | 110.25% |
Volatility is currently contracting
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that results from its pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM).
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript
Rhythm Pharmaceuticals, Inc. (NASDAQ: RGPX) reported that setmelanotide therapy produced robust, sustained and clinically significant weight loss in patients with acquired hypothalamic obesity at 2.5 years. Alongside the long-term setmelanotide results, Rhythm reported that bivamelagon therapy achieved progressive reductions in body mass index and hunger measures in patients with acquired hypothalamic obesity at one year.
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Saturday, June 13 at 9:00 a.m. ET/8:00 a.m. CT to discuss interim six-month results from the Company's Phase 2 trial evaluating setmelanotide in patients with Prader-Willi syndrome (PWS).
Rhythm Pharmaceuticals is transitioning from a development stage to a commercial rare disease leader, leveraging its IMCIVREE franchise for biologically defined obesity. IMCIVREE's recent FDA and EU approvals for acquired hypothalamic obesity unlock a significant, underserved market with rapid early uptake and global expansion potential. RYTM's premium valuation is justified by rapid revenue growth, multiple approved indications, global infrastructure, and a robust pipeline targeting rare neuroendocrine obesity.
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RYTM and any ticker you trade — then tracks every position and per-strategy win rate.
